ScottTTagawaMDMS

Genitourinary Oncology, Hematologic Oncology

Professor of Medicine & Urology; Medical Director, Genitourinary Oncology Research Program

Overview of Dr. Tagawa

Dr. Scott Tagawa is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, New York-Presbyterian Hospital, New York-Presbyterian Hospital, and NewYork-Presbyterian/Columbia University Irving Medical Center. He received his medical degree from University of Southern California School of Medicine and has been in practice 23 years. Dr. Tagawa accepts several types of health insurance, listed below. He is one of 378 doctors at New York-Presbyterian Hospital and one of 116 doctors at NewYork-Presbyterian/Columbia University Irving Medical Center who specialize in Oncology. He has more than 100 publications and over 500 citings.

Office
525 E 68th St
Starr 341 WCMC Division of Hematology Oncology
New York, NY 10065
Book by Phone+1(308) 210-4094

Fax+1 646-962-1603

Education & Training

Weill Cornell Graduate School of Medical SciencesMS, Clinical Investigation, 2007 - 2010
University of Southern California/LAC+USC Medical CenterFellowship, Medical Oncology, 2002 - 2005
University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Internal Medicine, 1998 - 2001
Keck School of Medicine of the University of Southern CaliforniaClass of 1998
Georgetown UniversityBS, Biology, 1989 - 1993

Certifications & Licensure

CA State Medical License 2000 - Present
NY State Medical License 2005 - 2024

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2012-2014
Top Doctors: New York Metro Area Castle Connolly, 2010-2014
America's Top Doctors for Cancer Castle Connolly, 2009, 2011-2013
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Treatment With Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Metastatic Prostate Cancer Start of enrollment: 2004 Aug 01
Completed
Phase 2
Radioimmunotherapy in Prostate Cancer Using 177Lu-J591 Antibody Start of enrollment: 2007 Aug 01
Completed
Phase 1
177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer Start of enrollment: 2009 Jun 01
Active, not recruiting
Phase 2
Study of Immunotherapy to Treat Advanced Prostate Cancer Start of enrollment: 2009 May 01
Completed
Phase 3
Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-resistant Prostate Cancer Start of enrollment: 2009 May 01
Completed
Phase 1
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
Completed
Phase 3
177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors Start of enrollment: 2009 Jul 01
Completed
Phase 1
Carboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate Cancer Start of enrollment: 2011 Mar 01
Terminated
Phase 2
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08
Active, not recruiting
Phase 3
Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer Start of enrollment: 2013 Jul 08
Completed
Phase 2
BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors Start of enrollment: 2013 Oct 01
Completed
Phase 1
A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer Start of enrollment: 2015 Jul 13
Completed
Phase 3
Neoadjuvant J591 Treatment for Prostate Cancer Start of enrollment: 2016 Feb 04
Completed
Phase 1
International Registry for Men With Advanced Prostate Cancer (IRONMAN) Start of enrollment: 2017 Jul 21
Recruiting
Roles: Contact, Principal Investigator
Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC Start of enrollment: 2020 Aug 18
Recruiting
Phase 1, Phase 2
Re-treatment 225Ac-J591 for mCRPC Start of enrollment: 2020 Oct 29
Recruiting
Early Phase 1
Phase I/II 225Ac-J591 Plus 177Lu-PSMA-I&T for Progressive Metastatic Castration Resistant Prostate Cancer Start of enrollment: 2021 Jun 30
Suspended
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

159 citations
Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device
Brian Kirby, Mona Jodari, Matthew S. Loftus, Gunjan Gakhar, Erica D. Pratt
Plos One. 2012-04-27
253 citations
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Ch...
Scott T. Tagawa, Arjun Vasant Balar, Daniel P. Petrylak, Arash Rezazadeh Kalebasty, Yohann Loriot
Journal of Clinical Oncology. 2021-04-30
550 citations
Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets
Himisha Beltran, David S. Rickman, Kyung Park, Sung Suk Chae, Andrea Sboner
Cancer Discovery. 2011-11-01

Lectures

TROPHY-U-01: A phase II open-label study of sacituzumab govitecan (IMMU-132) in patients with advanced urothelial cancer after progression on platinum-based chemothera...
ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019

Press Mentions

AACR: Philip Kantoff Discusses Convergent's Unique Path to Treating Prostate CancerApril 14th, 2022
Clinical Trial Equity in Radionuclide Treatment for Prostate Cancer - Joseph OsborneApril 7th, 2022
PSMA Imaging: A Multidisciplinary ApproachDecember 22nd, 2021
Join now to see all

Professional Memberships

American College of Physicians - ACP
Member
American Society of Clinical Oncology - ASCO
Member
American Urological Association - AUA
Member
American Society of Hematology - ASH
Member

External Links

Physician Profilehttp://www.weillcornell.org/physician/sttagawa/index.html

Insurance Accepted

Aetna Choice POS II
Aetna HMO
Altius Provider Directory
BCBS Blue Card PPO
BCBS Illinois BlueChoice Select
BCBS Illinois PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
First Health PPO
GHI PPO
Great West PPO
Healthfirst New York
HIP of New York - Select PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment